107.09 0.00 (0.00%)
After hours: 5:17PM EDT
|Bid||107.10 x 1400|
|Ask||107.11 x 1100|
|Day's Range||107.08 - 109.65|
|52 Week Range||88.17 - 132.13|
|Beta (3Y Monthly)||0.32|
|PE Ratio (TTM)||17.40|
|Earnings Date||Jul 30, 2019|
|Forward Dividend & Yield||2.58 (2.37%)|
|1y Target Est||124.33|
LAUSANNE, Switzerland, July 17, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a.
Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.
Jim Cramer said Monday on “ Mad Money " that Marvell Technology Group Ltd. (NASDAQ: MRVL ) is a buy, calling it the No. 1 5G name. Cramer doesn't like any auto companies and would avoid General Motors ...
INDIANAPOLIS, July 13, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the presentation of data about personal attitudes toward migraine among people without the disease.1 These data are from the OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) study. The findings demonstrate that discriminating attitudes towards people with migraine, unconscious or otherwise, are deep-rooted and advanced by a lack of understanding about the disease.1 They point to a need for greater respect for, and appreciation of, this serious neurologic disease.1 These data will be presented today, Saturday, July 13, 2019, at the 61st Annual Scientific Meeting of the American Headache Society taking place in Philadelphia. The OVERCOME study included more than 20,000 people with migraine and nearly 10,000 people without migraine.
Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.
A drug to treat Alzheimer's disease is increasingly proving elusive, despite billions of dollars spent on research and development. Johnson & Johnson (NYSE: JNJ )'s Janssen unit; Merck & Co., Inc. (NYSE: ...
INDIANAPOLIS, July 12, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced the upcoming presentation of data highlighting inconsistent and sub-optimal treatment patterns that people living with migraine experience across the U.S. healthcare landscape, specifically related to where they receive care.1 These data are from the OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) study, which collected responses from more than 20,000 people living with migraine. The results showed that people with migraine seek care in a variety of settings, with a significant portion seeking treatment in emergency department and urgent care settings.1 These findings will be presented on Saturday, July 13, 2019, at the 61st Annual Scientific Meeting of the American Headache Society taking place in Philadelphia.
INDIANAPOLIS, July 12, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the presentation of post-hoc analyses showing improvements in daily functioning and reductions in disability in patients with chronic and episodic migraine treated with Emgality® (galcanezumab-gnlm) compared to placebo.1 The analyses are based on data from three double-blind, placebo-controlled, Phase 3 pivotal studies of Emgality in chronic (REGAIN) and episodic migraine (EVOLVE-1 & EVOLVE-2).1 The data will be presented today at the 61st Annual Scientific Meeting of the American Headache Society (AHS) in Philadelphia. "Migraine is the second leading cause of disability in the U.S. and can severely impact people's lives," said Gudarz Davar, M.D., vice president, Neurology Development, Lilly Bio-Medicines.2 "Emgality gives people a chance to reduce their monthly migraine headache days.
The drug companies provide rebates to PBMs in exchange for distributing their products.
U.S. equities were hitting new record highs, with the Dow Jones Industrial Average topping 27,000 for the first time ever while the S&P 500 hits 3,000. The catalyst is an all too familiar one: The promise of more cheap money from the Federal Reserve, with chairman Jerome Powell strongly signaling a rate cut later this month in response to uneven economic data.But the gains are being trimmed in mid-day trading after a strong inflation report suggests the U.S.-China trade spat is starting to have an impact on import prices. And higher inflation would undermine the Fed's desire to lower rates. Stocks, obviously, wouldn't react well to that. * 10 Stocks to Sell for an Economic Slowdown A number of big drug stocks are getting hit amid the pullback on reports the Trump Administration has pulled its plan to eliminate rebates from government drug plans. Had this rule gone through, drug stocks would've been relatively unaffected. Investors now fear the administrations next move to try to lower drug prices. Here are four drug stocks to sell on the news:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pfizer (PFE) Click to EnlargePfizer (NYSE:PFE) shares are dropping hard out of a four-month uptrend threatening to cut below both its 50-day and 200-day moving averages. This comes after the stock bonked on resistance from its December high and remains mired in a sideways range that has been in play since last summer.The company will next report results on July 30 before the bell. Analysts are looking for earnings of 75 cents per share on revenues of $13.4 billion. When the company last reported on April 30, earnings of 85 cents per share beat estimates by 10 cents on a 1.6% rise in revenues. Eli Lilly (LLY) Click to EnlargeShares of Eli Lilly (NYSE:LLY) are falling down and out of a four month consolidation range, returning to levels not seen since December. This caps a decline of more than 15% from the highs hit in late March. With the 50-day and 200-day moving averages already lost, watch for a drop down to mid-2018 support near $105, which would be worth a loss of another 4% from here. * 3 Forgotten Tech Stocks Worth Remembering The company will next report results on July 30 before the bell. Analysts are looking for earnings of $1.45 per share on revenues of $5.6 billion. When the company last reported on April 30, earnings of $1.33 per share matched expectations on a 2.6% rise in revenues. Merck (MRK) Click to EnlargeMerck (NYSE:MRK) shares are dropping hard and fast away from the two-month consolation range that capped a nice 20% rally off of its 200-day moving average. The stock has gained more than 50% from the lows seen in early 2018 and a ripe for a significant profit taking pullback -- likely resulting in a revisiting of the April lows.The company will next report results on July 30 before the bell. Analysts are looking for earnings of $1.16 per share on revenues of $10.9 billion. When the company last reported on April 30, earnings of $1.22 per share beat estimates by 17 cents on a 7.8% rise in revenues. Bristol-Myers Squibb (BMY) Click to EnlargeShares of Bristol-Myers Squibb (NYSE:BMY) have returned to lows near $44 that have been tested multiple times in a pattern going back to early 2017. The range is rather wide, with prices down more than a third from the highs hit in February 2018. The company is continuing to work with regulators to waylay concerns over its proposed acquisition of Celgene (NASDAQ:CELG). * 10 Best ETFs for 2019: The Race for 1 Intensifies The company will next report results on July 25 before the bell. Analysts are looking for earnings of $1.06 per share on revenues of $6.1 billion. When the company last reported on April 25, earnings of $1.10 beat estimates by two cents on a 14% rise in revenues.As of this writing, William Roth held no positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell for an Economic Slowdown * 7 Marijuana Penny Stocks That I May Buy * 7 of The Best Schwab ETFs for Low Fees The post 4 Drug Stocks Getting Smashed appeared first on InvestorPlace.
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.
The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices
Drugmaker Eli Lilly and Co said on Thursday Christi Shaw, president of its bio-medicines business, would leave the company at the end of next month. Patrik Jonsson, general manager of Lilly Japan, will succeed Shaw, who joined the company in 1989. Shaw left the drugmaker in 2002 and later held senior positions at Novartis and in the Janssen and Ethicon units of Johnson & Johnson.
Mike Harrington, senior vice president and general counsel, will retire at the end of the year. Christi Shaw, senior vice president and president Lilly Bio-Medicines, has announced she will leave Lilly at the end of August.
INDIANAPOLIS, July 11, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that the New England Journal of Medicine published positive Phase 3 study results of Emgality® (galcanezumab-gnlm) for the treatment of episodic cluster headache.1 In this study, Emgality reduced the frequency of weekly cluster headache attacks across Weeks 1 to 3 compared to placebo.1 The U.S. Food and Drug Administration (FDA) approval of Emgality for the treatment of episodic cluster headache in adults in June 2019 was based on these results. "Cluster headache is one of the most severe primary headache disorders, with excruciatingly painful recurrent headache attacks and remarkably limited treatment options," said Peter Goadsby, M.D., PhD, Professor of Neurology at King's College London and lead author of the New England Journal of Medicine paper.
Investing.com -- Wall Street rose at the open on Thursday, as healthcare stocks reacted exuberantly to the administration abandoning a plan to curb drug rebates from government drug plans, pushing the Dow Jones Industrial Average above 27,000 for the first time.
INDIANAPOLIS, July 10, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the upcoming presentation of data indicating rising rates of opioid use for the treatment of migraine based on results from the OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) study.1 These findings will be presented on Saturday, July 13, 2019, at the 61st Annual Scientific Meeting of the American Headache Society taking place in Philadelphia. Despite opioids typically being reserved for limited or highly specific uses and not a treatment of choice for migraine, results from OVERCOME demonstrated that a high number of people are using opioids to treat their migraine.1,3 These findings suggest that the real-world treatment of migraine is falling short of current scientific understanding of how to optimally treat this serious and disabling neurologic disease.
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
INDIANAPOLIS , July 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2019 financial results on Tuesday, July 30, 2019 . Lilly will also conduct a conference call ...
A federal judge handed a big win to big pharma on Monday, saying a regulation that required drug companies to disclose drug prices in television ads was invalid.
Yahoo Finance's Brian Sozzi, Alexis Christoforous, and Anjalee Khemlani break down what's driving the health care sector higher.
Yahoo Finance's Adam Shapiro, Julie Hyman, Rick Newman, and Emily McCormick join HealthPrize Technologies CEO Tom Kottler to discuss.